AcuCort (ACUC) Life Science Conference 2026 summary

Market need and product overview

• Millions in EU and USA suffer from moderate to severe allergies, with a $3.1 billion market size for acute treatments.

• Current tablet treatments are complex and slow in emergencies, requiring water and preparation.

• ZeqmelitⓇ is a fast-dissolving oral film, easy to carry and use, providing a full dose in 15 seconds without water or medical staff.

• Approved for acute allergic reactions, croup in children, CINV, and COVID-19 patients with respiratory distress.

Clinical and market acceptance

• 9 out of 10 doctors would prescribe ZeqmelitⓇ if available; over 80% would use it for up to half their patients.

• Over 70% of patients prefer oral film to tablets; 24% had difficulty swallowing during severe reactions.

• 68% of patients required emergency care for severe allergic reactions; willingness to pay is significantly higher than product price.

Commercialization and partnerships

• Sales launched in Sweden, Norway, Finland, and Denmark; commercial agreement with Glenmark covers six European markets.

• Glenmark responsible for marketing, distribution, and regulatory filings in key European countries, with Germany as a reference market.

• Expansion strategy relies on global distributor and licensee network, with careful partner selection for each market.